Inmode Ltd (INMD)

$14.21 +0.45 (3.27%)
Market Cap 869.76M
Revenue (ttm) 394.82M
Net Income (ttm) 181.28M
EPS (ttm) N/A
PE Ratio 8.59
Forward PE 8.28
Profit Margin 45.91%
Debt to Equity Ratio 0.00
Volume 1,392,800
Avg Vol 1,245,808
Day's Range N/A - N/A
Shares Out 63.21M
Stochastic %K 91%
Beta 1.98
Analysts Sell
Price Target $17.05

Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well a...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 909 6313
Address:
Tavor Building, Sha’ar Yokneam PO Box 533, Yokne'am, Israel
future_tiger_cub
future_tiger_cub Jun. 25 at 8:37 PM
$INMD Netanjahu make Inmode great again
0 · Reply
LunkerInvesting
LunkerInvesting Jun. 25 at 6:40 PM
$INMD picked up 10k worth 13.75
0 · Reply
Tidus2021
Tidus2021 Jun. 24 at 5:55 PM
$INMD still below 20, i see
0 · Reply
Shortsnightmare
Shortsnightmare Jun. 23 at 11:05 PM
$INMD Well this stock dropped $1 when Israel started bombing Iran. It should move back up $1 now….assuming this ceasefire is for real.
0 · Reply
splitting_kings
splitting_kings Jun. 21 at 1:46 AM
$INMD i love you
0 · Reply
Awiz2
Awiz2 Jun. 20 at 12:53 PM
$INMD Conclusion: With an IV/P of 2.7, Inmode Ltd (INMD) appears to be trading at a meaningful discount to its intrinsic value. Its combination of high free cash flow yield, exceptional shareholder returns, and solid profitability makes it a compelling opportunity for value-focused investors. While the aesthetic industry may not carry the same glamour as tech or AI, Inmode’s fundamentals speak volumes — for those willing to look past the surface.
0 · Reply
Awiz2
Awiz2 Jun. 20 at 12:52 PM
$INMD IV/P for Inmode Ltd: 2.7 Inmode currently has an IV/P of 2.7, suggesting its intrinsic value is estimated at 2.7 times its current share price. That means: That’s a significant margin of safety — and a compelling signal for bargain hunters. Supporting Metrics: Free Cash Flow Yield: 12.2% A double-digit FCF yield underscores Inmode’s ability to generate serious cash relative to its market cap. Shareholder Yield: 38.21% Nearly 40% return of capital — largely through aggressive buybacks — is highly attractive in today’s market. Return on Assets (5-Year Average): 15.62% A strong and consistent measure of profitability that’s well above market averages.
0 · Reply
swingingtech
swingingtech Jun. 20 at 12:10 PM
$ESGV $INMD $LZ $ACLS https://wallstreetwaves.com/12-month-projection-for-esgv-by-implied-analyst/
0 · Reply
OptionRunners
OptionRunners Jun. 18 at 1:20 PM
$INMD fwiw https://x.com/MartinShkreli/status/1935054648471416933
1 · Reply
findingthestock
findingthestock Jun. 17 at 2:30 PM
$INMD STOP LOOKING AT VALUATION! it was said it was a good valuation at 60,50,40,30,20,15 Stock will decline bc of management, reduced and continue decline in sales especially North America and now geo regional tensions that will disrupt supply chain and hinder manufacturing There is no End to the stock drop or light at end of tunnel
0 · Reply
Latest News on INMD
InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

May 28, 2025, 8:30 AM EDT - 4 weeks ago

InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

May 9, 2025, 8:22 AM EDT - 6 weeks ago

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

InMode to Present at Upcoming Investor Conferences and Events

May 7, 2025, 8:30 AM EDT - 7 weeks ago

InMode to Present at Upcoming Investor Conferences and Events

InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

May 6, 2025, 8:03 AM EDT - 7 weeks ago

InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

InMode Q1 Earnings: Short-Term Catalysts Have Vanished (Rating Downgrade)

Apr 29, 2025, 7:00 AM EDT - 2 months ago

InMode Q1 Earnings: Short-Term Catalysts Have Vanished (Rating Downgrade)

InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)

Apr 29, 2025, 1:52 AM EDT - 2 months ago

InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)

Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City

Apr 28, 2025, 1:41 PM EDT - 2 months ago

Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City

InMode Ltd. (INMD) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 11:53 AM EDT - 2 months ago

InMode Ltd. (INMD) Q1 2025 Earnings Call Transcript

InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease

Apr 28, 2025, 7:00 AM EDT - 2 months ago

InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease

InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)

Apr 3, 2025, 4:26 AM EDT - 3 months ago

InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)

InMode to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:30 AM EDT - 3 months ago

InMode to Present at the 24th Annual Needham Virtual Healthcare Conference

InMode Responds to Doma Perpetual's Letters

Mar 6, 2025, 7:30 AM EST - 3 months ago

InMode Responds to Doma Perpetual's Letters

InMode to Present at Upcoming Investor Conferences

Mar 3, 2025, 8:30 AM EST - 4 months ago

InMode to Present at Upcoming Investor Conferences

InMode: Plastic Surgery Boom, Cash Flow, And Cheap

Feb 10, 2025, 1:14 AM EST - 4 months ago

InMode: Plastic Surgery Boom, Cash Flow, And Cheap

InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 9:08 AM EST - 4 months ago

InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript

InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program

Feb 4, 2025, 7:00 AM EST - 5 months ago

InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program

InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

Feb 3, 2025, 8:30 AM EST - 5 months ago

InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

InMode: A Clear Bargain With Unique Risks

Jan 28, 2025, 9:32 AM EST - 5 months ago

InMode: A Clear Bargain With Unique Risks

InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced

Jan 16, 2025, 7:00 AM EST - 5 months ago

InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback

Jan 15, 2025, 8:05 AM EST - 5 months ago

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback

InMode: Clearly, I Was Too Optimistic (Rating Downgrade)

Jan 10, 2025, 6:07 AM EST - 5 months ago

InMode: Clearly, I Was Too Optimistic (Rating Downgrade)

InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M

Jan 8, 2025, 7:00 AM EST - 6 months ago

InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M

InMode: Product Origination And Undervaluation Make The Stock A Buy

Dec 12, 2024, 1:17 AM EST - 7 months ago

InMode: Product Origination And Undervaluation Make The Stock A Buy

InMode: $25/Share Is Closer Than You Think

Nov 5, 2024, 9:43 AM EST - 8 months ago

InMode: $25/Share Is Closer Than You Think

InMode: A Deep Dive After Q3 Earnings

Oct 31, 2024, 12:16 PM EDT - 8 months ago

InMode: A Deep Dive After Q3 Earnings

InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 11:33 AM EDT - 8 months ago

InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript

InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)

Oct 30, 2024, 7:00 AM EDT - 8 months ago

InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)

InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

Oct 24, 2024, 7:03 AM EDT - 8 months ago

InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024

Oct 10, 2024, 7:00 AM EDT - 9 months ago

InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024

Stock Picks From Seeking Alpha's September 2024 New Analysts

Oct 4, 2024, 8:00 AM EDT - 9 months ago

Stock Picks From Seeking Alpha's September 2024 New Analysts

AME CCL CRWD CUK DVN EGO EMR

InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy

Oct 1, 2024, 7:00 AM EDT - 9 months ago

InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy

InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)

Sep 19, 2024, 7:14 AM EDT - 9 months ago

InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)

InMode Announces Share Repurchase Program of Up to 7.68 Million Shares

Sep 10, 2024, 7:00 AM EDT - 10 months ago

InMode Announces Share Repurchase Program of Up to 7.68 Million Shares

InMode Stock: An Inverse Bubble Caused By Short-Term Trouble

Sep 6, 2024, 4:38 AM EDT - 10 months ago

InMode Stock: An Inverse Bubble Caused By Short-Term Trouble

InMode to Present at 2024 Baird Global Healthcare Conference

Sep 4, 2024, 8:30 AM EDT - 10 months ago

InMode to Present at 2024 Baird Global Healthcare Conference

InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 11:19 AM EDT - 11 months ago

InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript

InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M

Aug 1, 2024, 7:00 AM EDT - 11 months ago

InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M

InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform

Jul 31, 2024, 8:03 AM EDT - 11 months ago

InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform

DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer

Jul 25, 2024, 8:15 AM EDT - 11 months ago

DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer

Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling

Jul 17, 2024, 8:03 AM EDT - 1 year ago

Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling

InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024

Jul 11, 2024, 8:30 AM EDT - 1 year ago

InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024

InMode: Reversing Previous Shareholder Dilution With Buybacks

Jun 13, 2024, 11:49 AM EDT - 1 year ago

InMode: Reversing Previous Shareholder Dilution With Buybacks

InMode to Present at Jefferies Healthcare Conference

May 16, 2024, 8:00 AM EDT - 1 year ago

InMode to Present at Jefferies Healthcare Conference

InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand

May 8, 2024, 8:03 AM EDT - 1 year ago

InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand

InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;

May 2, 2024, 7:00 AM EDT - 1 year ago

InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;

IMPORTANT DEADLINE TODAY: The Schall Law Firm Encourages Investors in InMode Ltd. with Losses of $500,000 to Contact the Firm

Apr 15, 2024, 9:00 AM EDT - 1 year ago

IMPORTANT DEADLINE TODAY: The Schall Law Firm Encourages Investors in InMode Ltd. with Losses of $500,000 to Contact the Firm

InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL

Apr 15, 2024, 7:00 AM EDT - 1 year ago

InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL

future_tiger_cub
future_tiger_cub Jun. 25 at 8:37 PM
$INMD Netanjahu make Inmode great again
0 · Reply
LunkerInvesting
LunkerInvesting Jun. 25 at 6:40 PM
$INMD picked up 10k worth 13.75
0 · Reply
Tidus2021
Tidus2021 Jun. 24 at 5:55 PM
$INMD still below 20, i see
0 · Reply
Shortsnightmare
Shortsnightmare Jun. 23 at 11:05 PM
$INMD Well this stock dropped $1 when Israel started bombing Iran. It should move back up $1 now….assuming this ceasefire is for real.
0 · Reply
splitting_kings
splitting_kings Jun. 21 at 1:46 AM
$INMD i love you
0 · Reply
Awiz2
Awiz2 Jun. 20 at 12:53 PM
$INMD Conclusion: With an IV/P of 2.7, Inmode Ltd (INMD) appears to be trading at a meaningful discount to its intrinsic value. Its combination of high free cash flow yield, exceptional shareholder returns, and solid profitability makes it a compelling opportunity for value-focused investors. While the aesthetic industry may not carry the same glamour as tech or AI, Inmode’s fundamentals speak volumes — for those willing to look past the surface.
0 · Reply
Awiz2
Awiz2 Jun. 20 at 12:52 PM
$INMD IV/P for Inmode Ltd: 2.7 Inmode currently has an IV/P of 2.7, suggesting its intrinsic value is estimated at 2.7 times its current share price. That means: That’s a significant margin of safety — and a compelling signal for bargain hunters. Supporting Metrics: Free Cash Flow Yield: 12.2% A double-digit FCF yield underscores Inmode’s ability to generate serious cash relative to its market cap. Shareholder Yield: 38.21% Nearly 40% return of capital — largely through aggressive buybacks — is highly attractive in today’s market. Return on Assets (5-Year Average): 15.62% A strong and consistent measure of profitability that’s well above market averages.
0 · Reply
swingingtech
swingingtech Jun. 20 at 12:10 PM
$ESGV $INMD $LZ $ACLS https://wallstreetwaves.com/12-month-projection-for-esgv-by-implied-analyst/
0 · Reply
OptionRunners
OptionRunners Jun. 18 at 1:20 PM
$INMD fwiw https://x.com/MartinShkreli/status/1935054648471416933
1 · Reply
findingthestock
findingthestock Jun. 17 at 2:30 PM
$INMD STOP LOOKING AT VALUATION! it was said it was a good valuation at 60,50,40,30,20,15 Stock will decline bc of management, reduced and continue decline in sales especially North America and now geo regional tensions that will disrupt supply chain and hinder manufacturing There is no End to the stock drop or light at end of tunnel
0 · Reply
ChristinaC
ChristinaC Jun. 17 at 2:11 PM
$INMD The management team is gonna run this stock to the ground if the status quo persists. This is the worst stock to invest in. Fire the bunch and revamp the team fuck!
0 · Reply
findingthestock
findingthestock Jun. 16 at 4:33 PM
$INMD their operations are near the areas that have been targeted They should release a statement letting everyone know the current conditions of their manufacturing and supply chain
1 · Reply
Shortsnightmare
Shortsnightmare Jun. 16 at 3:43 PM
$INMD This company has zero debt and $8.40 per share in cash. If you adjust their inventory for the mark-up they achieve on their equipment (80 pct gross margin) you can add another $4.10 per share in cash. So almost $13 per share in liquidity. Plus the value of the patents etc. It’s mathematically impossible for the stock to trade much lower than it is. Its entire market cap is backed my cash and inventory…..no brainer here.
0 · Reply
BlockheadCapital
BlockheadCapital Jun. 16 at 2:56 PM
$INMD single digits on tap ?
0 · Reply
findingthestock
findingthestock Jun. 15 at 12:55 AM
$INMD @TheBiotechInvestor_ Looking at numbers wouldn’t tell you that Inmode was urged to move their facilities out of Israel due to regional conflict and supply chain disruptions They ignored it Looking at the numbers will not give you the full picture The stock is declining and things in the region is looking bad
0 · Reply
findingthestock
findingthestock Jun. 14 at 9:42 PM
$INMD MOSHE was urged by DOMA to move its facilities out of Israel As usual Moshe did not follow Moshe and Inmode management is not competent and the reason why the stock has gone from 90s and towards $10S and lower In a recent letter to DOMA, Mr. Mizrahy refused to consider moving a portion of production outside of Israel, a move that would decrease potential risks as well as help to trim costs and grow margins
0 · Reply
JoeBeets007
JoeBeets007 Jun. 13 at 7:21 PM
$INMD I remember when people couldn’t get enough of this at $150 before the split!
0 · Reply
OptionRunners
OptionRunners Jun. 13 at 6:52 PM
$INMD Buyer of the January 16th 2026 $12.50 puts 3,800 times for $1.40
0 · Reply
findingthestock
findingthestock Jun. 13 at 2:17 PM
$INMD Can this go to $10 based on economic conditions and geo tensions Yes it can Stock has been down trending and I been warning investors especially newbies who look at numbers and think it’s good value based investment but don’t do any other research Stock from 90s to lows for a reason
0 · Reply
findingthestock
findingthestock Jun. 13 at 12:50 AM
$INMD with Israel and Iran conflict the stock will likely drop considerably
0 · Reply
findingthestock
findingthestock Jun. 12 at 3:53 PM
$INMD Been listening to and read every earnings call and nothing has changed or will changed and that’s why the stock keeps declining It’s easy to look at balance sheet and think Inmode is a good value based picked but then you would be down if that’s all you looked at Stock from all time highs and near lows and closer to $10 then $20 Large stakeholders like DOMA have lost confidence in management as shareholder return dwindles
0 · Reply
findingthestock
findingthestock Jun. 12 at 1:52 PM
$INMD it has potential could and was said by others when stock was trading 50,45,35,30,25 etc The balance sheet does not give a clear picture and only those who listen and read the earnings call transcript will have the full idea why Inmode stock continues to DROP
0 · Reply